Interpace Biosciences 2025 Annual Report: Key Investor Insights and Potential Share Price Movers

1. Executive Summary and Key Highlights

Interpace Biosciences, Inc. has released its Annual Report for the fiscal year ended December 31, 2025. This comprehensive report contains several important developments, risk factors, and financial data that investors and shareholders must closely consider. The following article summarizes the most critical information that may impact the company’s future and share price.

2. Company Status and Capital Structure

• Public Float and Share Information: As of June 30, 2025, the aggregate market value of Interpace Biosciences’ common stock held by non-affiliates was approximately \$2.63 million. As of March 20, 2026, there were 27,700,904 shares of common stock outstanding, each with a \$0.01 par value.
• Delisting from Major Exchanges: The company’s common stock was delisted from Nasdaq and subsequently removed from trading on the OTCQX as of August 18, 2025. The stock now trades on the OTCID, which has adversely affected the share price and the company’s ability to raise capital through public markets.
• Concentration of Ownership: Two private equity firms—Ampersand and 1315 Capital—together control 84% of the company’s outstanding shares (Ampersand: 50%, 1315 Capital: 34%). This high concentration of ownership gives them substantial influence over board decisions, mergers, acquisitions, and other critical matters, which may deter changes in corporate control or strategic direction.
• Preferred Stock: The company may issue additional preferred stock, which could dilute common shareholders and negatively affect share value.

3. Business Performance and Strategic Developments

• Business Focus: Interpace’s business model is centered around molecular diagnostic tests for thyroid cancer (notably, ThyGeNEXT® and ThyraMIR®v2). The company discontinued its pancreatic cancer test, PancraGEN®, in May 2025 due to the loss of CMS reimbursement. All current revenues are dependent on its molecular diagnostics for thyroid cancer.
• Revenue Streams: The company’s revenues are fully dependent on clinical services, with a significant reliance on third-party reimbursement (private insurance and government programs). Any changes in reimbursement rates or policies could materially affect financial performance.
• Growth Strategy: Interpace aims to expand organically and through potential licensing, acquisitions, or mergers. Focus areas include:
  • Expanding awareness and use of existing products (ThyGeNEXT® and ThyraMIR®v2)
  • Implementing automation and operational efficiencies
  • Broadening coverage and reimbursement for clinical tests
  • Adding new technologies and products through partnerships or acquisitions
  • Leveraging internal managed care teams and Key Opinion Leaders to secure payer contracts
  • Investing in R&D for new diagnostic solutions and bioinformatics data utilization
• Financial Flexibility and Liquidity: The company has historically relied on secured promissory notes from its private equity investors, a revolving credit facility, and term loans. However, raising new funds has become more difficult after the Nasdaq delisting and the company is currently ineligible to use a Form S-3 shelf registration statement.

4. Market and Industry Environment

• The global esoteric molecular diagnostics market is expected to grow from \$29.6 billion in 2025 to \$75.9 billion by 2034 (CAGR: 11.12%). Interpace sees significant opportunity in this space due to the potential for its tests to reduce unnecessary surgeries and healthcare costs.
• The company’s growth prospects are tied to the expansion of molecular diagnostics in the U.S. and globally, but also faces competitive and regulatory pressures.

5. Major Risks and Potential Share Price Movers

Risks Potentially Affecting Share Value:

• Dependence on Third-Party Reimbursement: Any reduction, delay, or rescinding of reimbursement from insurers or government agencies can significantly impact revenues and cash flow.
• Regulatory and Legal Risks: The company is exposed to evolving regulations, especially those related to laboratory developed tests (LDTs), and must comply with extensive federal, state, and international requirements.
• Concentration of Shareholder Control: The dominance of two private equity firms could impede mergers, acquisitions, or other strategic changes, potentially suppressing the share price or making hostile takeovers difficult.
• Financial Reporting and Internal Controls: The company recently restated prior period financial statements, which may affect investor confidence and reputation. Any future weaknesses in internal controls could further damage trust and hurt the share price.
• Billing and Collections: The company describes the complexity of its billing process and the risk of errors, delays, or non-payment. Deterioration in accounts receivable could materially weaken the financial position.
• Delisting and Capital Access: The delisting from Nasdaq and removal from OTCQX has already adversely impacted the stock price, market liquidity, and the company’s ability to raise funds.
• Market Volatility and Dilution: The share price may be highly volatile due to all the above risks and the potential for further dilution via additional preferred stock or equity issuance.
• Operational Risks: The company relies on third parties for key materials and billing services. Any disruption in supply chains or billing provider performance could negatively affect operations and financial results.

6. Forward-Looking Statements

The company has provided various forward-looking statements regarding its business plans, growth strategies, and expectations. However, management cautions that these statements are subject to known and unknown risks, uncertainties, and assumptions. Actual results may differ materially from those projected.

7. Action Points for Investors

• Monitor reimbursement developments closely, as these will have a direct impact on revenues and cash flow.
• Watch for any announcements regarding financing, strategic partnerships, or acquisitions/mergers, which may alter the company’s growth trajectory and capital structure.
• Pay attention to regulatory changes affecting molecular diagnostics and LDTs, which can significantly affect the company’s operations.
• Track share ownership and possible transactions by the two controlling private equity investors, as large sales or changes in control could move the stock price.
• Be alert for further restatements or disclosures relating to internal controls, as investor confidence may be sensitive to these issues.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions. The information herein is based on the company’s 2025 Annual Report and may be subject to change. The author and publisher do not accept any liability for actions taken based on this information.

View INTERPACE BIOSCIENCES, INC. Historical chart here